CDCaroline Dehais

Caroline Dehais

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caroline Dehais has a total of 253 co-authors. Here are the top co-authors by number of shared publications:

  • Mehdi Touat

    Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de Neuro-oncologie, Paris, France

    12 shared publications
  • Franck Bielle

    Sorbonne Université, Paris Brain Institute-ICM, Inserm, CNRS, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Department of Neuropathology, Paris, France

    11 shared publications
  • Ahmed Idbaih

    Sorbonne Université, AP-HP, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuro-Oncologie-Institut de Neurologie, F-75013, Paris, France

    10 shared publications
  • Bertrand Mathon

    AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Neurosurgery, Paris, France

    8 shared publications
  • Lucia Nichelli

    Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Equipe labellisée Ligue Nationale contre le Cancer Paris France

    8 shared publications
  • Marc Sanson

    Groupe Hospitalier Pitié-Salpêtrière

    8 shared publications

Latest Publications

  • Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas

    by Connor J. Kinslow, Giuseppe Minniti, Paul D. Brown, Michael A. Vogelbaum, Karla V. Ballman, Ann Mercurio, Markus D. Siegelin, Emre Kocakavuk, Kyle Tuohy, Alireza Mansouri, et al.

    PURPOSE: Age ≥40 years is regarded as a high-risk feature and an indication for adjuvant chemoradiotherapy for patients with lower-grade glioma in clinical practice guidelines. It is unclear whether age remains a relevant prognostic factor for contemporary definitions of lower-grade gliomas in the molecular era. METHODS: The Prospective Gliomas Research (PROGRES) database contains individual patient-level data from 11 prospective clinical trials or observational registries of histologically defined lower-grade 2-3 oligodendroglioma or astrocytoma. We determined the association of age (18-39 years v ≥40 years) with progression-free survival (PFS) stratified by isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) status, using log-rank tests and Cox regression models. We validated our findings in a separate multi-institutional retrospective cohort (Retrospective Glioma Research [REGRES] database). RESULTS: We identified 1,619 and 1,292 eligible patients in the PROGRES and REGRES cohorts, respectively. IDH -wildtype tumors were more common in patients 40 years and older (38% v 5%, odds ratio: 11.3 [95% CI, 6.5 to 19.7]). Age was associated with PFS in IDH -wildtype (5-year PFS for ≥40 v 18-39 years: 6% v 24%, hazard ratio [HR], 1.74 [95% CI, 1.21 to 2.50]) but not in IDH -mutant glioma (60% v 59%, HR, 0.89 [95% CI, 0.76 to 1.05], P interaction < .001). In IDH -wildtype tumors, older age predicted aggressive molecular features, including TERT promoter mutation (65% v 28%), EGFR amplification (41% v 15%), and chromosome +7/–10 alteration (57% v 25%). In a pooled analysis of four clinical trials, age was not predictive of a benefit from chemoradiotherapy versus radiotherapy alone for IDH -mutant glioma. CONCLUSION: In the absence of additional clinical or molecular risk factors, age alone should not be considered an indication for administration or deferral of adjuvant treatment. Practice guidelines should be revised to reflect contemporary prognostic factors in the molecular era.


  • Open Access

    Gliomas with pleomorphic and pseudopapillary features ( GPAP ) are circumscribed tumors with targetable mutations, prolonged survival, and frequent tumor predisposition

    by Alberto Picca, Valeria Barresi, Aude Trinquet, Luca Bertero, Lucia Nichelli, Guillaume Chotard, Michèle Bernier, Thomas Gareau, Salah Eddine Oussama Kacimi, Jaydutt Bhalshankar, et al.

    DNA methylation profiling of CNS tumors led to the identification of HPAP (high‐grade glioma with pleomorphic and pseudopapillary features), a recently proposed entity with variable morphology, recurrent MAP‐kinase pathway activating events, and longer survival compared to glioblastoma. We aimed to independently validate and further characterize this entity. We retrieved a multicentric cohort of gliomas compatible with HPAP and performed t‐SNE dimensionality reduction on their DNA methylation profile. Clinical, radiological, histological, and molecular data were reviewed. Twenty tumors clustering with previously reported HPAP cases were identified. Median age at diagnosis was 37 years. Radiologically, the tumors appeared as expansive lesions with heterogeneous enhancement and frequent cysts. Histologically, they were well‐circumscribed, with papillary and pleomorphic features variably present. Marked histological signs of aggressivity were present in seven. Immunostainings showed expression of GFAP, OLIG2, and CD34. All cases were IDH1/2 wildtype and pMGMT unmethylated. Recurrently mutated genes included TP53 , ATRX , RB1, and BRAF . Five patients had germline pathogenic variants in genes associated with hereditary tumor predisposition syndromes ( MLH1 , BRCA2 , CHEK2 , NF2 , RB1 ). All patients underwent surgical resection, but subsequent management was heterogeneous. Ten‐year estimated survival was 85%. CDKN2A homozygous deletion seemed to identify more aggressive tumors. In conclusion, our data suggest the existence of a novel entity of circumscribed gliomas with long‐term survival despite possible high‐grade histological presentation, for which we propose the nomenclature “Gliomas with pleomorphic and pseudopapillary features” with a spectrum encompassing provisory grade 2 and 3. A proper identification could guide treatment choices.

  • Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma

    by Diana D. Shi, Ester Calvo Fernández, Vinesh T. Puliyappadamba, Tyler A. Lanman, Yi Xiao, Zebin Wen, Maria Minor, Diego Prost, Aleksandra B. Lasica, Feng Cai, et al.

    The mutant isocitrate dehydrogenase 1/2 inhibitor (mIDHi) vorasidenib was recently incorporated into clinical treatment guidelines for IDH-mutant gliomas, although its impact on chemoradiation is unclear. Specifically, it is unknown whether upfront mIDHi exposure alters subsequent chemoradiation efficacy. Addressing this critical question has been challenging because of limited clinical data and a paucity of mIDHi-responsive preclinical glioma models. We first established that a genetic mouse model of IDH-mutant astrocytoma developed by our group was responsive to vorasidenib monotherapy. We then used this mouse to address whether mIDHi alters the response to chemoradiation after progression on mIDHi. Mice that received upfront vorasidenib followed by chemoradiation at progression had improved survival compared with control mice receiving vehicle followed by chemoradiation. We then compiled real-world data and early outcomes from 29 patients who were among the first to receive mIDHi followed by radiation with or without chemotherapy. Our study directly addresses uncertainty surrounding therapy sequencing that has emerged after introduction of vorasidenib as a first-line treatment for IDH-mutant glioma. Our empirical preclinical data demonstrate that prior mIDHi treatment enhances chemoradiation sensitivity of IDH-mutant glioma.


  • Open Access

    Supplementary Figure S2 from 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Individual longitudinal changes in PET MTV and FLAIR volumes during treatment. For each patient, changes in PET-derived MTV (red line) and FLAIR lesion volume (blue line) are plotted over time, with treatment initiation marked as day 0. Numeric values indicate the change in volume at each time point, referenced either to baseline or to the lowest value observed (best response) in cases with multiple follow-ups. Each panel represents the data for a single patient.

  • Open Access

    Supplementary Figure S1 from 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Multimodal imaging assessment. A) Comparison of FLAIR volumes obtained from PET MTV with diffusion (apparent diffusion coefficient [ADC], mm²/s) and perfusion (relative cerebral blood volume [rCBV]) maps, shown at baseline and follow-up for patients 2 and 8. B) Longitudinal evolution of T1-weighted gadolinium-enhanced (T1G) lesions during treatment for patients 2, 8, and 18 (images for patient 15 unavailable), displayed alongside their corresponding PET images.

  • Open Access

    Supplementary Figure S3 from 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Waterfall Plot of Individual Tumor Responses by PET and MRI Criteria. Individual percentage changes from baseline for metabolic tumor volume (MTV, RANO-PET 1.0, red bars), sum of products of diameters (SPD, light blue bars), and volumetric FLAIR (dark blue bars). Dashed lines indicate the partial response thresholds for each respective criterion. Below the plot, information is provided for each patient regarding the presence of baseline contrast-enhancing T1G lesion, progression during IDH inhibitor therapy according to RANO criteria, PFS in months.

  • Open Access

    Supplementary Figure S4 from 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Exploratory comparison of baseline 18F-DOPA-PET values in progressors (n=6) vs non-progressors (n=14) on IDH inhibitor treatment. Parameters include metabolic tumor volume (MTV), total lesion glycolysis (TLG), tumor-to-background maximum ratio (TBRmax), and mean ratio (TBRmean). P-values were calculated using the Mann-Whitney U test.

  • Open Access

    Data from 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2-Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Purpose:Small-molecule inhibitors targeting isocitrate dehydrogenase (IDH) 1/2–mutant proteins have demonstrated benefit in IDH1/2-mutant gliomas. However, responses assessed by conventional MRI measurements are infrequent, delayed, and difficult to interpret, highlighting the need for early biomarkers of treatment benefit. In this study, we investigated 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine positron emission tomography (18F-DOPA-PET) and MRI responses in patients with IDH1/2-mutant glioma receiving IDH inhibitors (IDHi).Experimental Design:Patients with IDH1/2-mutant glioma receiving IDHi as part of trials or expanded access programs with pre- and posttreatment MRI and 18F-DOPA-PET were included. Evaluations included 2D/3D measurements on T2-weighted fluid-attenuated inversion recovery images; T1-post-contrast, perfusion, and diffusion imaging for MRI; and metabolic tumor volume (MTV), total lesion glycolysis, and tumor-to-background ratios (TBR) for 18F-DOPA-PET. Disease response evaluation using volumetric assessments, RANO 2.0, and PET RANO 1.0 criteria were compared and correlated with outcomes.Results:From 2021 to 2025, 20 patients with IDH1/2-mutant glioma (8 with astrocytoma and 12 with oligodendroglioma) receiving IDHi (4 receiving ivosidenib and 16 receiving vorasidenib) were analyzed. Significant reductions in 18F-DOPA-PET parameters including TBRmean, TBRmax, and MTV were observed in 10 of 20 patients, aligning with observed changes in perfusion and diffusion imaging. Nine partial responses and one complete response were identified using 18F-DOPA-PET, whereas both volumetric and standard 2D morphologic MRI assessments indicated stable disease as best response. PET response on MTV was correlated with prolonged tumor control.Conclusions:These results highlight the potential of 18F-DOPA-PET and advanced MRI sequences as valuable complements to standard RANO 2.0 MRI evaluations for assessing treatment response in patients with glioma undergoing IDHi therapy.

  • 18F-DOPA-PET and Advanced MRI Improve Treatment Response Assessment in IDH1/2 -Mutant Gliomas Treated with IDH Inhibitors

    by Diego Prost, Lucia Nichelli, Laura Rozenblum, Alice Laurenge, Caroline Dehais, Bertrand Mathon, Julian Jacob, Louisa Drouiche, Angel Escamilla-Ramírez, Caroline Houillier, et al.

    Purpose: Small-molecule inhibitors targeting isocitrate dehydrogenase (IDH) 1/2–mutant proteins have demonstrated benefit in IDH1/2-mutant gliomas. However, responses assessed by conventional MRI measurements are infrequent, delayed, and difficult to interpret, highlighting the need for early biomarkers of treatment benefit. In this study, we investigated 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine positron emission tomography (18F-DOPA-PET) and MRI responses in patients with IDH1/2-mutant glioma receiving IDH inhibitors (IDHi). Experimental Design: Patients with IDH1/2-mutant glioma receiving IDHi as part of trials or expanded access programs with pre- and posttreatment MRI and 18F-DOPA-PET were included. Evaluations included 2D/3D measurements on T2-weighted fluid-attenuated inversion recovery images; T1-post-contrast, perfusion, and diffusion imaging for MRI; and metabolic tumor volume (MTV), total lesion glycolysis, and tumor-to-background ratios (TBR) for 18F-DOPA-PET. Disease response evaluation using volumetric assessments, RANO 2.0, and PET RANO 1.0 criteria were compared and correlated with outcomes. Results: From 2021 to 2025, 20 patients with IDH1/2-mutant glioma (8 with astrocytoma and 12 with oligodendroglioma) receiving IDHi (4 receiving ivosidenib and 16 receiving vorasidenib) were analyzed. Significant reductions in 18F-DOPA-PET parameters including TBRmean, TBRmax, and MTV were observed in 10 of 20 patients, aligning with observed changes in perfusion and diffusion imaging. Nine partial responses and one complete response were identified using 18F-DOPA-PET, whereas both volumetric and standard 2D morphologic MRI assessments indicated stable disease as best response. PET response on MTV was correlated with prolonged tumor control. Conclusions: These results highlight the potential of 18F-DOPA-PET and advanced MRI sequences as valuable complements to standard RANO 2.0 MRI evaluations for assessing treatment response in patients with glioma undergoing IDHi therapy.


  • Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma

    by Salah Eddine O Kacimi, Caroline Dehais, Loïc Feuvret, Olivier Chinot, Catherine Carpentier, Charlotte Bronnimann, Elodie Vauleon, Apolline Djelad, Elizabeth Cohen-Jonathan Moyal, Olivier Langlois, et al.

    PURPOSE: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 IDHmt/Codel ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemotherapy regimen between procarbazine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), and vincristine (PCV) and temozolomide (TMZ) remains unclear given the lack of randomized trial data comparing both regimens. METHODS: The objective was to assess the overall survival (OS) and progression-free survival (PFS) associated with first-line PCV/RT versus TMZ/RT in patients newly diagnosed with O3 IDHmt/Codel . We included patients with histologically proven O3 IDHmt/Codel (according to WHO criteria) from the French national prospective cohort Prise en charge des OLigodendrogliomes Anaplasiques (POLA). All tumors underwent central pathologic review. OS and PFS from surgery were estimated using the Kaplan-Meier method and Cox regression model. RESULTS: 305 newly diagnosed patients with O3 IDHmt/Codel treated with RT and chemotherapy between 2008 and 2022 were included, of which 67.9% of patients (n = 207) were treated with PCV/RT and 32.1% with TMZ/RT (n = 98). The median follow-up was 78.4 months (IQR, 44.3-102.7). The median OS was not reached (95% CI, Not reached [NR] to NR) in the PCV/RT group and was 140 months (95% CI, 110 to NR) in the TMZ/RT group (log-rank P = .0033). On univariable analysis, there was a significant difference in favor of PCV/RT in both 5-year (PCV/RT: 89%, 95% CI, 85 to 94; TMZ/RT: 75%, 95% CI, 66 to 84) and 10-year OS (PCV/RT: 72%, 95% CI, 61 to 85; TMZ/RT: 60%, 95% CI, 49 to 73), which was confirmed using the multivariable Cox model adjusted for age, type of surgery, gender, Eastern Cooperative Oncology Group performance status, and CDKN2A homozygous deletion (hazard ratio, 0.53 for PCV/RT, 95% CI, 0.30 to 0.92, P = .025). CONCLUSION: In patients with newly diagnosed O3 IDHmt/Codel from the POLA cohort, first-line PCV/RT was associated with better OS outcomes compared with TMZ/RT. Our data suggest that the improved safety profile associated with TMZ comes at the cost of inferior efficacy in this population. Further investigation using prospective randomized studies is warranted.